Article Sidebar

PDF
Date Published: 08/07/2022
Online Published: 08/07/2022
Abstract Views: 296
Views PDF: 167
DOI: https://doi.org/10.55046/vjrnm.33.567.2019
Issue
No. 33 (2019)
Section
Scientific research
How to Cite
Tran, L. S., & Bui, V. G. (2022). Computed tomography features of lung cancer patients before tyrosine kinase inhibitor treatment and response assessment by recist 1.1. Vietnamese Journal of Radiology and Nuclear Medicine, 33, 57-62. https://doi.org/10.55046/vjrnm.33.567.2019

Computed tomography features of lung cancer patients before tyrosine kinase inhibitor treatment and response assessment by recist 1.1

Trần Lê Sơn1,, Bui Van Giang1
1 Hanoi Medical University

Main Article Content

Abstract

SUMMARY


Objective:
1. Describe computed tomography features of non-small cell lung cancer before tyrosine kinase inhibitor treatment.
2. Treament response assessment by RECIST 1.1.
Patients and method: Cross-sectional, retrospective and prospective study of 36 non- small cell lung cancer patients, EGFR mutations positive, treated with Tyrosine Kinase Inhibitor from 08/2018 to 06/2018, having Computed Tomography image after 3 and 6 months treament.
Results: Tumors located mainly in peripheral of the lung (77,8%). The most common position is the right upper lobe (30,5%), the least common position is the right middle lobe (5,6%). There are 83,3% of tumors with the size over 3cm. 100% of tumor have irregular and spicules magin. Solid mass accounted for 63,9%, partly solid mass
(33,3%), one tumor is cavity form. Medium attenuation value is 27 HU in pre-contrast and 57,1 HU in post-contrast CT scan. Lymph node
metastasis in 27 (61%) patients. Lymph node metastasis is mainly occured in paratracheal nodes [2,4(R,L), 3] (48%), A-Pwindow, paraaortic
nodes (5,6) (12%), subcarinal nodes (7) (16%), supraclavicular nodes (1) (20%). After 3 months treament, partial response: 17 patients
(52,8%), stable disease: 19 patients (47,2%). After 6 months treament, partial response: 14 patients (38,9%), stable disease: 20 patients (55,6%),
progressive disease: 2 patients (5,5%).
Conclusion:
1. Computed TomographyFeatures can be used to diagnose lung cancer.
2. Tyrosine Kinase Inhibitor Treatment is effective inadvancednonsmall cell lung cancer.

Article Details

Keywords

lung cancer, computed tomography, tyrosine kinase inhibitor treatment, Recist 1.1

References

TÀI LIỆU THAM KHẢO
1. Jemal A, Bray F, Ward E. et al (2011). Global cancer statistics. CA Cancer J Clin, 61(2), 69-90.
2. Teh, Elaine and Belcher, Elizabeth. (2014). Lung cancer: Diagnosis, staging and treatment.Cardiothoracic surgery, 242-248.
3. Cung Văn Công (2016). Nhận xét một số đặc điểm hình ảnh cắt lớp vi tính và mô bệnh học của ung thư phổi ở các bệnh nhân điều trị tại Bệnh viện phổi trung ương. Tạp chí Y học quân sự số 306(5-6/2015).
4. Nguyễn Đình Hướ ng (2011), “Chọc sinh thiết xuyên thành ngực các khối u phổi dướ i hướ ng dẫn của cắt lớp vi tính đa dãy: nhận xét qua 280 trườ ng hợp tại bệnh viện Ung bướ u Hà Nội”, Y học thực hành. 773(7), pp. 41-43.
5. Kiessling F et al (2004). Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring?, Eur. Radiol, 14(7). p. 1226-33.
6. M. Nishino, H. Hatabu, B. E. Johnson et al (2014). State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology, 271(1), 6-27
7. T. S. Mok, Y. L. Wu, S. Thongprasert et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361(10), 947-957.
8. Nguyễn Minh Hà, Trần Huy Thịnh và cộng sự (2014). Erlotinib bước một trên bệnh nhận ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến gen EGFR.Tạp chí nghiên cứu y học, 91(5), 6-12